Nancy A Grygiel Implements A Sell Strategy: Offloads $483K In Amgen Stock
What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...
Mena FN6d
Repatha Global Market Report 2025: An In-Depth Look At Market Sizes, Growth Trends, And Key Industry Players
Repatha evolocumab is a form of treatment for cardiovascular diseases ... Major companies operating in the repatha market include industry giant Amgen Inc. Their significant presence and ...
Amgen Inc. (AMGN): ‘Absurd That This Stock Sells for 14x Earnings’ – Jim Cramer on Blockbuster Drugs
We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going ...
Amgen's Broad Portfolio Strength and Wide Moat Should Protect Profits Despite Upcoming Biosimilars
Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...
pharmaphorum6d
Scotland says no to Daiichi Sankyo’s cholesterol drug Nilemdo
High peak sales projections for drugs to treat high cholesterol haven’t always been accurate, as can be seen from a glance at the sales figures for Amgen’s Repatha (evolocumab) and Sanofi ...
Seeking Alpha6d
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's diversified portfolio includes 14 blockbuster medicines, with standout growth in Repatha and Evenity, and promising pipeline developments, particularly for MariTide. Despite patent ...